In ₹ Crore except Per Share Latest Annual | SMSPHARMA FY26 | INDSWFTLAB FY26 | SOLARA FY26 | DCAL FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 37.31× | 76.57× | — | ◆ 26.88× | 51.72× -28% | |
| P/B | 4.96× | 2.38× | 2.50× | ◆ 0.39× | 2.38× +108% | |
| EV/EBITDA | 24.61× | 63.58× | 20.34× | ◆ 8.12× | 20.34× +21% | |
| Market Cap | ₹3,896 Cr | ₹3,291 Cr | ₹3,142 Cr | ₹2,621 Cr | ₹3,142 Cr +24% | |
| Growth | ||||||
| Revenue CAGR 3Y | ◆ 19.32% | -19.01% | -1.76% | 6.71% | -1.76% +1198% | |
| Revenue CAGR 5Y | ◆ 9.51% | — | -3.27% | 8.93% | 2.83% +236% | |
| Net Income CAGR 3Y | — | -4.53% | — | — | -4.53% | |
| Revenue YoY (latest Q) | 5.57% | ◆ 25.35% | 19.57% | -4.29% | 19.57% -72% | |
| Net Income YoY (latest Q) | 2.04% | ◆ 181.32% | 55.04% | -347.24% | 55.04% -96% | |
| Profitability | ||||||
| EBITDA Margin | ◆ 19.31% | 7.03% | 13.64% | 19.29% | 13.64% +42% | |
| Net Income Margin | ◆ 11.50% | 6.46% | -0.54% | 3.32% | 3.32% +246% | |
| Return on Common Equity | ◆ 12.99% | 2.99% | -0.59% | 1.46% | 1.46% +790% | |
| Return on Capital Employed | ◆ 13.01% | 1.02% | 6.05% | 2.36% | 2.36% +451% | |
| Return on Assets | ◆ 7.49% | 2.47% | -0.32% | 0.82% | 0.82% +813% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.46× | ◆ 0.01× | 0.53× | 0.42× | 0.42× +10% | |
| Interest Coverage | 5.69× | ◆ 10.31× | 0.92× | 1.30× | 1.30× +338% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹887 Cr | ₹641 Cr | ₹1,369 Cr | ₹2,932 Cr | ₹1,369 Cr -35% | |
| Net Income | ₹102 Cr | ₹41.4 Cr | −₹7.4 Cr | ₹97.5 Cr | ₹41.4 Cr +146% | |
| Total Assets | ₹1,362 Cr | ₹1,673 Cr | ₹2,333 Cr | ₹11,923 Cr | ₹2,333 Cr -42% | |
| EPS | ₹11.15 | ₹4.95 | ₹-1.68 | ₹6.22 | ₹4.95 +125% | |
| Book Value per Share | ₹83.91 | ₹159.38 | ₹282.08 | ₹425.82 | ₹282.08 -70% | |